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Case presentation
A 48-year-old woman was evaluated at Michael Reese Hospital and
Medical Center for accelerated hypertension. Hypertension had been
diagnosed 10 years earlier and had been well managed with routine
medications until 18 months ago. At that time, blood pressure became
progressively more difficult to control despite administration of pro-
pranolol, nifedipine, and chlorthalidone.
She was hospitalized 6 months ago; physical examination revealed a
well-nourished black woman in no apparent distress. Temperature was
37.3° C; blood pressure, 264/130 mm Hg; pulse, 86/mm and regular;
respirations, 22/mm and regular. There were no hemorrhages, exu-
dates, or papilledema on funduscopic examination. Cardiac examina-
tion revealed an S4 and a 1/VI systolic ejection murmur. No abdominal
bruits were heard. The remainder of the examination was unremark-
able.
Laboratory data included a white blood cell count of 9200/mm3 with
a normal differential. The hematocrit was 44%; serum sodium, 139
mEq/liter; potassium, 2.9 mEq/liter; bicarbonate, 31 mEq/liter; chlo-
ride, 90 mEq/liter; BUN, 10 mg/dl; and serum creatinine, 1.1 mg/dl.
Urinalysis revealed a specific gravity of 1.011; pH, 7.0; protein, 3+;
occult blood, 1 -y; and 2 red blood cells and 6 white blood cells/high-
power field.
Thyroid function tests and urinary excretion rates for metanephrine,
eateeholamines, and vanillylmandelic acid all were within reference
range. A renal angiogram showed 99% stenosis of the proximal right
renal artery, 75% stenosis of the left renal artery, and severe infrarenal
aol-tic atherosclerosis. The renal vein renin was not measured. A
percutaneous right renal artery angioplasty was performed. Blood
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pressure fell to 130/70 mm Hg in the immediate aftermath of the
angioplasty but hypertension returned over the next few days. She was
discharged and advised to take propranolol, hydrochlorothiazide, and
hydralazine.
Over the ensuing 3 weeks, blood pressure rose despite compliance
with medications, reaching 180/105 mm Hg. A second angiogram
revealed 40% stenosis of the right renal artery and 80% stenosis of the
left renal artery. A left renal artery angioplasty was technically unsuc-
cessful. An aortorenal thromboendarterectomy was then performed,
and bilateral patch grafts were placed. Blood pressure at the time of
discharge was 190/90 mm Hg without antihypertensive medications.
One week later the blood pressure was 170/tOO mm Hg. The patient
was treated with nadolol and hydrochlorothiazide, but the blood
pressure continued to rise, reaching 230/130 mm Hg 4 months after the
aortorenal thromboendarterectomy. Alpha-methyldopa, 250 mg 4 times
daily, was added to the regimen, and the blood pressure fell within one
week to 150/100 mm Hg. Another angiogram revealed a patent left renal
artery and a 50% to 90% stenosis of the right renal artery immediately
distal to the patch graft.
Discussion
DR. SUZANNE OPARIL (Profrssor of Medicine and Associate
Professor of Physiology and Biophysics, and Director, Hyper-
tension Research Program, The University of Alabama at
Birmingham, Birmingham, Alabama): This woman had a his-
tory typical of patients with atherosclerotic renovascular hyper-
tension: longstanding hypertension that had been well con-
trolled on routine antihypertensive medications until 18 months
prior to admission, when her blood pressure became difficult to
control despite appropriate triple therapy. She presented with
accelerated hypertension, hypokalemia (which probably repre-
sented a consequence of her hyperreninemic state in combina-
tion with the effects of chlorthalidone therapy and no potassium
chloride replacement), and 3 + proteinuria with occult blood in
the urine. Renal angiography revealed severe stenosis of the
proximal right renal artery, less severe but apparently signifi-
cant stenosis of the left renal artery, and severe infrarenal aortic
atherosclerosis. Renal vein renin studies were not obtained.
Percutaneous right renal artery angioplasty apparently was
successful in that (1) the blood pressure immediately fell to the
normal range, and (2) a second angiogram performed approxi-
mately one month later revealed only 40% stenosis of the right
renal artery. Nevertheless, hypertension recurred in the 3
weeks following angioplasty and the second angiogram revealed
80% stenosis of the left renal artery, After unsuccessful left
renal artery angioplasty, an aortorenal thromboendarterectomy
was performed and bilateral patch grafts were placed.
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Percutaneous renal angioplasty
The choice of percutaneous renal angioplasty for the initial
treatment of this patient is reasonable, because the relatively
noninvasive nature, the low cost, and the low morbidity of this
procedure—as well as the ease of repetition if stenosis recurs—
represent major advantages over surgical revascularization of
the kidney. Complications of renal angioplasty, including oc-
elusion of the renal artery secondary to intimal dissection or
thrombosis, renal artery perforation, retroperitoneal bleeding,
and balloon rupture, are uncommon but not rare. In two large
series, the complication rates were 11% and 12.5%, and com-
plications were much more common in patients with atheroscle-
rotic lesions than in those with fibromuscular disease of the
renal artery [I, 2]. Further, the cure or improvement rate of
hypertension following percutaneous dilation of the renal artery
is less in patients with atherosclerotic disease than in those with
fibromuscular disease and less in bilateral than in unilateral
disease. Thus this patient falls into a relatively unfavorable
prognostic category.
In the largest reported long-term followup study of percuta-
neous transluminal renal angioplasty in renovascular hyperten-
sion (89 patients: 51 with atheromatous and 31 with fibromus-
cular disease, 65 with unilateral and 24 with bilateral stenoses),
angioplasty was technically successful (residual stenosis, less
than 50% of the luminal diameter) in 57% of unilateral athero-
matous stenoses and in only 10% of bilateral atheromatous
lesions compared with 87% of unilateral flhromuscular stenoses
12]. The higher technical failure rate in the atherosclerotic
disease group was attributed to greater severity of the stenoses,
which led to complete occlusion of the renal artery in 5 patients,
or to location of lesions at the ostium of the renal artery (5
patients), causing resistance to dilation. Following successful
angioplasty, hypertension improved or was cured in 84% of
patients with atheromatous disease and in 93% of patients with
flbromuscular dysplasia after a mean followup period of 16
months (range, 4 to 40 months). In a more recent series in which
60 patients underwent initially successful renal angioplasty (35
with atherosclerotic and 25 with fibromuscular lesions), hyper-
tension was cured (mean followup period, 21.6 months; range,
1 to 65 months) in 29% of patients with atherosclerotic lesions
and in 50% with flbromuscular lesions; high blood pressure
improved in 48% of patients with atherosclerotic lesions and in
32% with fibromuscular stenoses [I]. Recurrence of significant
renal artery stenosis (50% to 80% occlusion) was observed in
35% of' patients with atherosclerotic lesions (7 of 20) and in 15%
of patients with fibromuscular lesions (2 of 13). Second dilation
is often effective treatment for recurrent renal artery stenosis
following successful renal artery dilation [31 or for the fibrotic
scarred lesions at the site of previous renal arterial repair [4],
Thus repeat dilation represents a viable approach to the future
treatment of the patient under discussion.
Renal vein renin was not measured in this patient prior to
either of the angioplasties or surgical revascularization. In view
of the complexity of her lesions and her unsatisfactory response
to renal revascularization therapy to date, renin data might have
been useful in her earlier management and could be helpful in
deciding whether to attempt dilation of the stenotic anastomosis
site in the right renal artery. The usefulness of renal vein renin
ratios in predicting the outcome of surgical renal revasculariza-
tion and of angioplasty has been much debated. Although renal
vein renin determinations have been used for years to predict
the antihypertensive efficacy of surgery in patients with reno-
vascular hypertension [5—7], in many patients with no difference
in renal vein renins, surgery has produced excellent blood
pressure responses [8—11]. In two large series from Europe, no
differences in pre-angioplasty renal vein renin ratios were found
among subgroups of patients with unilateral renal artery steno-
sis who were subsequently cured, improved, or unimproved by
the procedure [1, 12]. In contrast, other groups have reported
that renal vein renin determinations have value in predicting the
long-term success of angioplasty in patients with renovascular
hypertension [13, 14]. Further, a return of previously abnormal
renal vein renin ratios to the normal range has been observed in
patients whose hypertension was cured by angioplasty,
whereas persistence of a significant difference was found in
patients with unsuccessful angioplasty or restenosis [3]. In a
more recent study, however, repeat determination of renal vein
renin ratios 7 months after percutaneous transluminal dilation
of the renal artery showed that renal vein renin ratios decreased
regardless of whether the patient was cured, improved, or
unimproved [11. Whether the apparent differences in prognostic
usefulness of renal vein renin ratios among published series
relate to differences in antihypertensive medications adminis-
tered prior to testing, differences in methods of renin assay, or
to other variables remains to be determined.
Renovascular surgery
In contrast to percutaneous renal angioplasty, surgery for
renovascular hypertension carries a mortality rate ranging from
0% to 21% and a rate of major complications of 10% to 15% in
published series [15]. In addition to the skill of the surgeon,
other important determinants of mortality in surgery for reno-
vascular hypertension are coronary artery disease, impaired
preoperative renal function, left ventricular hypertrophy, com-
plex renal surgical procedures, and concurrent extrarenal sur-
gery [15, 161. The death rate in patients with bilateral disease is
twice that of patients with unilateral disease; the mortality rate
is three times higher in patients with atherosclerotic disease
than in those with fibromuscular disease [16]. Several groups
have reported very low mortality (1% to 2%) and morbidity
rates in renal vascular surgery [17—19]. These more favorable
results have been attributed to more sophisticated preoperative
screening, preoperative correction of coexisting coronary or
cerebrovascular disease, and employment of methods of revas-
cularization such as hepatorenal, splenorenal, or ileorenal by-
pass or autotransplantation, which obviate operation on a
severely diseased aorta [18].
The overall surgical cure rate of patients with hypertension
secondary to unilateral renal artery stenosis is 40% to 50%; the
improvement rate is approximately 50%, and the failure rate is
10%. Results in unilateral disease are better than in bilateral
disease [15, 16]. Results in patients with fibromuscular disease
are better than in those with arteriosclerotic disease, and
morbidity and mortality rates are lower in the former group.
Preoperative duration of hypertension is an important predictor
of the outcome of renal vascular surgery. In one study, 78% of
patients who had had hypertension for less than 5 years prior to
surgery, but only 25% of those who had had hypertension for
more than 5 years, showed a favorable blood pressure response
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[20]. When only patients with atherosclerotic disease were
considered, improvement rates were 67% in the less-than-5-
year group versus 13% for the more-than-S-year group; in
patients with fibrous dysplasia, improvement rates were 88% in
the less-than-5-year group versus 39% for the more-than-5-year
group. Duration of hypertension thus should be added to the
renal vein renin ratio as an important prognostic factor in
assessing the possible outcome of renal vascular surgery. By
these criteria, the patient we are discussing today falls into a
high risk/low likelihood of benefit category for surgical renal
re vascularization, so that surgery appropriately was undertaken
only after drug therapy and angioplasty had failed.
The sympathetic nervous system in renovascular hypertension
Human data. The final aspect of this patient's course on
which I would like to comment and which will serve as the
focus for the remainder of my discussion is her dramatic
response to a modest dose of aipha-methyldopa. She had severe
hypertension refractory to treatment with the combination of a
beta-adrenergic blocker and a thiazide diuretic. Persistent hy-
pertension presumably was due to stenosis at the site of the
patch graft to the right renal artery. Yet the systolic blood
pressure fell by 80 mm Hg and the diastolic pressure by 30 mm
Hg within one week of the addition of alpha-methyldopa, 250
mg 4 times daily, to the regimen. Aipha-methyldopa is metab-
olized by dopa decarboxylase to alpha-methyldopamine, which
is then metabolized by dopamine-f3-hydroxylase to alpha-
methylnorepinephrine. This active metabolite lowers blood
pressure largely through activation of central a2-adrenergic
receptors in the region of the nucleus tractus solitarius, with a
resultant reduction in sympathetic outflow [2 1—23]. The pro-
found antihypertensive effect of alpha-methyldopa in this pa-
tient therefore provides indirect evidence in support of a major
sympathetic component underlying her renovascular hyperten-
sion.
A growing body of evidence implicates the sympathetic
nervous system in the pathogenesis of renovascular hyperten-
sion in humans. Clinical and laboratory investigations have
demonstrated that sympathetic nervous system activity is en-
hanced in patients and animals with established renovascular
hypertension and that sympatholytic agents lower blood pres-
sure in these subjects. Increased plasma norepinephrine levels
[24] and increased urinary excretion of catecholamines and
their metabolites [25, 26] have been reported in patients with
renovascular hypertension compared with patients with essen-
tial hypertension and with normotensive subjects. Figure 1
depicts venous plasma catecholamine levels in 8 patients with
renovascular hypertension (the "renovascular" group) whose
hypertension was subsequently cured or improved following
renal revascularization or nephrectomy and in 9 patients with
essential hypertension in whom renovascular disease was ruled
out by an exhaustive diagnostic evaluation [24]. In adrenal
venous plasma, norepinephrine, epinephrine, and dopamine
levels all were higher in the renovascular group than in the
essential hypertension group; in low inferior vena caval plasma,
only norepinephrine was elevated in the renovascular group.
These data provide evidence for activation of the sympathoad-
renal system in the renovascular group.
Norepinephrine levels in peripheral venous blood represent
an indirect and imprecise index of sympathetic activity; spill-
RV EH
Fig. I. Simultaneous catecholamine levels in left adrenal venous (panel
a) and low inferior vena caval (panel b) plasma in patients with
renovascular hypertension (RV, n = 8) and essential hypertension(EH, n = 9). Values are expressed as umol/liter. Means for each group
+ 1 SEM are given. NA = noradrenaline; A = adrenaline, and D =
dopamine. Reproduced with modifications from [24].
over into the circulation from the site of production depends on
many factors, including release rate, specific binding to recep-
tor sites, nonspecific uptake by nonneuronal tissues, reuptake
by nerve endings, enzymatic degradation, and blood flow [27].
Nevertheless, in the absence of a more direct and precise
method of quantifying sympathetic activity in human subjects,
plasma norepinephrine measurements generally have been ac-
cepted as a useful noninvasive means of assessing sympathetic
activity in clinical studies. Further, because the catecholamine-
rich adrenal responds specifically to sympathetic stimulation,
adrenal venous catecholamines might offer a more sensitive
index of sympathetic activity than do circulating catechola-
mines sampled from other sites [24].
Urinary excretion of catecholamines [251 and/or catechola-
mine metabolites [261 is increased in patients with renovascular
hypertension. Januszewicz and Wocial compared 50 patients
who had renovascular hypertension (39 with unilateral and 11
with bilateral renal artery stenosis) with control groups corn-
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Fig. 2. Responses of blood pressure (BP) and urinary noradrenaline
excretion (NA) to captopril (CE!) administration and surgical
revascularization of the stenotic kidney in a 32-year-old male with
reno vascular hypertension secondary to unilateral renal artery
stenosis. Reproduced with permission from [25],
prising 45 patients with essential hypertension and 20 healthy
normotensive subjects. The mean urinary excretion of vanil-
lylmandelic acid in patients with renovascular hypertension was
6.5 1.4 mg124 hr. a value significantly higher (P < 0.01) than
that in the normotensive (4.1 1.2 mg/24 hr) or the essential
hypertensive (4.3 1.7 mg/24 hr) control groups [261. Urinary
excretion of metanephrine, normetanephrine, and catechola-
mines did not differ significantly in the renovascular group as a
whole compared with the control groups, but in the subgroup of
patients with renovascular hypertension and either elevated
peripheral plasma renin activity or elevated renal vein renin
ratios, urinary norepinephrine excretion was significantly ele-
vated (P <0.02) compared with controls. These observations
provide additional evidence that the sympathetic nervous sys-
tem is stimulated in patients with renovascular hypertension
and, further, that sympathetic hyperactivity is somehow linked
to activation of the renin-angiotensin system in this syndrome.
Izumi et al reported a patient with renovascular hypertension
and elevated urinary norepinephrine levels who responded to
oral captopril therapy with normalization of both blood pres-
sure and norepinephrine excretion (Fig. 2) [25j. Subsequent
surgery—autotransplantation of the stenotic kidney into the
abdominal cavity—led to normalization of blood pressure,
norepinephrine excretion, and plasma renin activity. These
findings are consistent with previous demonstrations of angio-
tensin-induced activation of the sympathetic nervous system
[28—341.
To assess the role of the central nervous system in the
maintenance of renovascular hypertension, the effects of cloni-
dine on blood pressure and plasma norepinephrine have been
examined in patients with hypertension secondary to unilateral
renal artery stenosis [351. Clonidine is an imidazoline derivative
that lowers blood pressure largely through activation of central
cs2-adrenergic receptors, with a resultant reduction in sympa-
thetic outflow [36, 37]. Administration of a single 300 g oral
dose of clonidine to 9 patients with moderate to severe
renovascular hypertension resulted in the hemodynamic and
humoral changes summarized in Figure 3 [35]. Systolic and
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Fig. 3. Blood pressure, heart rate, plasma renin activity, and plasma
noradrenaline levels in 9 patients with unilateral renal artery .rtenosis
before (—0.25 and 0) and 1, 2, 4, 6, and 8 hours after 300 pg of oral
clonidine. Reproduced with modifications from [351.
diastolic blood pressure decreased significantly within the first
hour, reached a nadir at 4 hours, and remained depressed at 8
hours. Heart rate also fell to a nadir at 4 hours. Plasma renin
activity remained unchanged, whereas plasma norepinephrine
decreased from a mean of 288 34 pg/mI to 96 33 pg/mI (P <
0.02) at the sixth hour. Although an effect of clonidine on
neurons in the spinal cord or peripheral presynaptic a2-
adrenoceptors cannot be excluded, the decline in plasma nor-
epinephrine levels most likely reflects diminished sympathetic
outflow due to the central effects of clonidine.
'I'aken together, these data provide evidence for a role of
central pressor mechanisms, probably linked to angiotensin II
and central sympathetic activation, in the maintenance of
hypertension in patients with unilateral renal artery stenosis.
The one-kidney, one-clip (IK,IC) hypertensive rat. Increased
sympathetic nervous system activity contributes to the mainte-
nance of hypertension in the IK,JC model [38—45]. Because
plasma norepinephrine is elevated in IK,IC hypertension,
peripheral sympathetic activity is likely increased [421. Further,
Eide and colleagues found increased tyrosine hydroxylase
activity and norepincphrine content in the hypothalamus of
IK,lC hypertensive rats 2 weeks after renal artery clipping and
suggested that central noradrenergic activity is altered in this
model [45]. Central sympatholytic interventions, including
treatment with intracisternal 6-hydroxydopamine or creation of
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Time after clipping (weeks)
Fig. 4. Effects of renal denervation on blood pressure in the one-kidney,
one-clip rat. Arrow indicates the time of renal denervation or sham
operation. Reprinted with permission from [851.
lesions in the posterior hypothalamus, prevent or attenuate
hypertension in the IK,IC model [39, 40].
To assess the role of the renal sympathetic nerves in the
maintenance of hypertension in the lK,lC model, Katholi,
Winternitz, and I examined the effects of renal denervation or
sham operation performed 2 weeks after clipping of the left
renal artery in uninephrectomized rats [46]. Renal denervation
significantly decreased blood pressure without producing con-
comitant alterations in daily water or sodium intake, sodium
excretion, plasma renin activity, or creatinine clearance (Fig.
4). Plasma norepinephrine concentration fell from elevated
levels (422 42 pg/mI) to the normal range (273 22 pg/ml)
following renal denervation [471. Further, ganglionic blockade
in 1K,lC animals resulted in a significantly greater decrease in
blood pressure than in renal-denervated lK,1C or uninephrec-
tomized control animals. These data indicate that the fall in
blood pressure following renal denervation in 1K,lC hyperten-
sive rats is, in part, secondary to a decrease in peripheral
sympathetic activity. Blood pressure in the denervated animals
rose again to hypertensive levels by 5 weeks after renal
denervation. This finding suggested reinnervation, and repeated
renal denervation resulted in a significant decrease in blood
pressure.
Studies in which total renal denervation is employed to assess
the role of the renal afferent nerves in the pathogenesis of
hypertension are subject to two important interpretive diffi-
culties. First, the afferent as well as efferent nerves are dam-
aged, so the unique role of each can only be inferred indirectly
from an analysis of physiologic indicators of renal efferent
nerve activation, such as sodium excretion and plasma and
renal renin contents. Second, peripheral denervation is not
permanent, Within a few days following denervation, peripheral
processes of the damaged nerves establish growth cones on
Time after clipping (weeks)
Fig. 5. Mean systolic (tail cuff) blood pressure in denervated, sham-
operated, and control groups, demonstrating the effect of denervajion
of renal afferent nerves on the course of one-kidney, one-clip
renovascular hypertension in the rat. A single asterisk signifies a
significant difference between the sham-operated and control groups, a
double asterisk signifies that the sham group's mean blood pressure is
significantly elevated above both that of denervated and control groups,
and a solid triangle signifies that a significant difference exists between
the denervated and control groups. Reprinted with permission from
[53].
their proximal ends and begin to grow back toward the dener-
vated organ [48—501. By 6 weeks after denervation, the kidney
appears to be nearly completely reinnervated, As an index of
reinnervation of the kidney, norepinephrine stores were moni-
tored following the profound depletion seen in the first few days
after peripheral renal denervation. An increase became appar-
ent approximately 3 weeks after denervation, and renal norep-
inephrine stores were nearly normal by 6 weeks after [51].
Blood pressure followed a similar course.
Dorsal root denervation leads to more permanent loss of
renal sensory feedback than does total renal denervation.
Following removal of a 2 mm segment, the central neural
processes do not have the ability to reestablish their central
connections, at least not during the first 2 months following
surgery [521. Further, dorsal rhizotomy is selective in that renal
afferent neurons are cut but renal efferent axons remained
undamaged.
In a recent study, we directly assessed the role of the renal
afferent nerves in the pathogenesis of lK,1C hypertension by
observing the effect of rhizotomy of T8-L2 dorsal spinal nerves
on the subsequent course of blood pressure [531. The nerves
were cut one week prior to renal artery clipping or sham
operation in uninephrectomized rats. Figure 5 summarizes the
blood pressure responses to renal artery clipping in rhizotom-
ized and sham-operated animals. Blood pressure of the sham-
operated group rose progressively over the 5 weeks after
clipping, reaching 185 9 mm Hg. In contrast, blood pressure
of the denervated rats leveled off in the borderline hypertensive
range (140 to 150mm Hg). It was significantly lower than that of
the sham group and significantly higher (15 to 20 mm Hg) than
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that of the nonclipped control group. Thus 1K, IC hypertension
is attenuated rather than abolished by dorsal rhizotomy, a result
reminiscent of that previously obtained with total renal
dencrvation [46]. Failure of blood pressure to normalize follow-
ing either of these interventions suggests that factors other than
the renal nerves contribute to the development and mainte-
nance of hypertension in this model.
In a subsequent series of experiments, Wyss, Aboukarsh,
and I examined the role of the afferent renal nerves in the
maintenance of 1K,IC hypertension using a similar technique
[531. The 1K,IC hypertensive animals were subjected to sec-
tioning of the T8-L2 dorsal roots, and the effects of the
intervention on blood pressure were assessed. Dorsal rhizoto-
my lowered blood pressure from a mean of 217 mm Hg systolic
to 171 mm Hg systolic for 2 weeks (P < 0.05), but by 3 weeks
after rhizotomy, blood pressure returned to prerhizotomy lev-
els. This finding contrasts with the longer-lasting antihyperten-
sive effect of dorsal rhizotomy performed prior to clipping.
The dorsal rhizotomy data directly demonstrate that the renal
afferent nerves play a role in the pathogenesis of renovascular
hypertension. Nevertheless, it should be recognized that the
loss of renal afferent feedback to the central nervous system is
probably accompanied by an alteration in the firing rate of the
pre- and postganglionic renal efferent neurons, Because a
complete peripheral lesion of the renal nerve in the IK,IC
hypertensive rat does not alter indices of efferent renal nerve
function (such as sodium excretion and renal renin content), we
have assumed that the efferent nerves play little or no role in
this form of hypertension [46]. Further studies must be carried
out to assess more directly the possible contribution of alter-
ations in renal sympathomotor innervation to the pathogenesis
of renovascular hypertension.
To examine the hypothesis that interruption of the renal
nerves decreases central sympathetic activity as well, Winter-
nitz, Katholi, and I examined the effects of total renal denerva-
tion on central norepinephrine stores [541. In these experiments
renal denervation or sham operation was, as in earlier studies
[46], performed 2 weeks after clipping; one week later the rats
were sacrificed by decapitation without anesthesia. Spinal
cords and brains were removed, and the hypothalamus,
midbrain, and pons/medulla were isolated and later analyzed for
catecholamine content using high-pertbrmance liquid chroma-
tography with electrochemical detection, Renal denervation
significantly reduced hypothalamic norcpinephrine content
without altering hypothalamic dopamine content (Fig. 6), but
did not change the norepinephrine or dopamine contents of
other brain regions studied. These data, combined with the
finding of a decrease in peripheral sympathetic activity follow-
ing renal denervation, suggest that the renal afferent nerves play
a role in established I K, IC hypertension by modulating central
sympathetic nervous system activity.
The two-kidney, one-clip (2K, IC) hypertensive rat. Studies
from our laboratory of the effects of renal denervation on 2K,lC
hypertension in the rat provide additional evidence that the
renal afferent nerves are involved in the pathogenesis of exper-
imental hypertension [55]. Denervation of the clipped kidney in
2K,lC hypertensive rats performed 6 weeks after renal artery
clipping causes significant attentuation of hypertension 155].
Plasma norepinephrine levels and the depressor response to
ganglionic blockade in 2K,lC hypertensive rats were increased
r
control Sham Denervated
Fig. 6. Hypothalamic norepinephrine (left) and dopamine (right) stores
in one—kidney control; one—kidney, one—clip shamn—operaled; and one—
kidney, one-clip renal denervated rats, The asterisk indicates that the
sham-operated rats displayed significantly (P 0.01) higher levels of
norepinephrine than did the other two groups. Reprinted with permis-
sion from [851.
in comparison to levels in normotensivc unclipped controls.
Denervation of the clipped kidney returned both the plasma
norcpinephrine and the depressor response to ganglionic block-
ade to control levels. In contrast, denervation of the nonclipped
kidney did not alter blood pressure or plasma norepinephrine
levels. As in the 1K,IC animals, these results indicate that
attentuation of hypertension following renal denervation in
2K,IC hypertension is accompained by a decrease in peripheral
sympathetic activity.
To assess the role of the central nervous system in the
maintenance of chronic 2K,lC hypertension in the rat, the
effects of clonidine on blood pressure and plasma norepineph-
rine have been examined in that model [56]. In the rat with
chronic (12 to 16 week) 2K,lC hypertension, oral administra-
tion of clonidine (50 cg/kg/day for 7 days) lowered blood
pressure and urinary norepinephrine excretion significantly
(Fig. 7) [56]. Further, plasma renin activity t'ell significantly in
2K,IC hypertensive and normotensive control rats treated with
clonidine. The decreases in blood pressure and renin were
positively correlated (r = 0.78, P < 0.01) in 2K,lC rats. These
data provide evidence for a role of central pressor mechanisms,
probably linked to angiotensin II and central sympathetic
activation, in the maintenance of hypertension in the 2K,lC
model.
Angiotensin II acts on the central nervous system, adrenal
medulla, sympathetic ganglia, and sympathetic nerve terminals
to enhance neural activity [291. At the level of the peripheral
nerve terminal, angiotensin II facilitates norepinephrine re-
lease, inhibits reuptake, and potentiatcs vascular responses to
norepinephrine [29, 32, 331. It also has been suggested that
angiotensin II stimulates norcpincphrine biosynthesis in sym-
pathetically innervated tissues [28]. In experimental renovascu-
lar hypertension, increased endogenous angiotensin II produc-
tion results in elevated circulating norepinephrine concentra-
tions [30, 31]. Further, experimental studies demonstrate in-
creased norepinephrine release in the cutaneous vascular bed of
dogs in the chronic phase of two-kidney, one- or two-clip
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depressor effect of renal denervation is at least partly secondary
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ity in established renovascular hypertension, the stimulus for
150 — afferent renal nerve discharge must he identified. Some re-
E 140 —
searchers have reasoned that, because the renal nerves play a
-- long-term role in the maintenance of hypertension, the receptor
130 —
for afferent renal nerve stimulation is more likely to be a
—_______-___..—---__—__
chemoreceptor than a mechanoreceptor [58—611. Mechanore-
120 —
1 ceptors characteristically reset their activation thresholds in
response to a chronic change in pressure, whereas chemorecep-
tors do not. Recent studies have identified adenosine as a likely
40 - candidate for stimulating chemoreceptive nerve endings in
renovascular hypertension [62—64]. Katholi and associates have
provided experimental evidence that renal adenosine release
20 - increases during the moderate ischemia induced by renal artery
stenosis, and they have speculated that this increase in adeno-
-2
_____________________________________________
sine release might activate the sympathetic nervous system via
the afferent renal nerves [641. The relationship between intra-
-
________
renal adenosine-induced sympathetic nervous system activa-
.5 \ tion and the pathogenesis of renovascular hypertension merits\ ** further study.
20 - \
Evidence from generic models
The spontaneously hypertensive rat of the Ol'amoto strain.
Evidence from a number of laboratories suggests that the
sympathetic nervous system, via the eft'rent renal nerves,
40 - plays a role in the pathogenesis of hypertension in the sponta-
neously hypertensive rat of the Okamoto strain (SHR). In this
20 — model, increased renal efferent nerve activity contributes to the
development of hypertension by causing increased renal so-
dium retention [511. Renal denervation delays the development
and blunts the severity of hypertension [51, 65, 661. This delay
is associated with increased urinary sodium excretion and thus
Time (days) suggests a renal efferent mechanism. The effect of renal dener-
Fig. 7. Effects of clonidine (50 pg/kg/day >< 7 days) on systolic blood vation on the subsequent development and/or maintenance of
pressure and urinary noradrenaline excretion in chronic 2K,JC (•S) hypertension in SHR critically depends on the age of the
and IK,IC (0—0) renal hypertensive and normotensive control (A—A) animals when the kidneys are denervated [51]. In 7-week-old
rats. * P < 0.05, P < 0.005, P < 0.001 compared with pretreat-
ment values. Reproduced with modifications from [561. (early hypertensive) SHR, renal denervation delays the onset
and slows the rate of development of hypertension (Fig. 8).
These alterations are associated with a significantly larger
percentage of ingested sodium being excreted in the urine
Goldblatt hypertension [34]. Finally, both centrally adminis- during the first 3 weeks after denervation, as compared with
tered exogenous angiotensin II and endogenous angiotensin II sham-operated controls (Fig. 8). By the fifth week after dener-
synthesized in the central nervous system elevate blood pres- vation, renal norepinephrine content increases to near control
sure by stimulating specific angiotensin 11 receptors in brain values, suggesting reinnervation, and blood pressure and so-
which, in turn, appear to activate sympathetic outflow. dium excretion in the two groups converge. Measurements of
Chronic coarctation hypertension in the dog. Bilateral renal the renal norepinephrine content of animals sacrificed at 1, 3,
denervation in dogs with experimental hypertension caused by and 6 weeks following denervation demonstrate a significant
chronic aortic coarctation results in a decrease in blood pres- direct correlation (r = 0.65, P < 0.01) between blood pressure
sure unaccompanied by changes in sodium excretion or plasma and renal norcpinephrine content. Further, repeat denervations
renjn activity [57]. Thus the effects of renal denervation in this at 3-week intervals result in a chronic attentiation of hyperten-
model appear not to be due to interruption of the renal efferent sion in this model [67]. In contrast to the effects of denervation
nerves. As in IK,lC and 2K,IC hypertension, there was in young animals, renal denervation does not alter blood
evidence of decreased peripheral sympathetic activity following pressure or sodium excretion in 18-week-old SHR with estab-
renal denervation. Taken together, these studies suggest that in lished hypertension. Thus, renal sympathetic nerves contribute
a number of experimental models, the renal afferent nerves to the development of hypertension in the SHR, at least in part,
contribute to the maintenance of hypertension and that the by causing increased urinary sodium retention, but the renal
I I
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'—. Control (n = 8) activity of SHR to be twice that in control WKY [75]. Other
investigators have failed to confirm these findings, however.
Francisco et a! found no differences in efferent renal nerve
activity between SHR and WKY [771, and Touw and colleagues
found that the elevated vascular resistance observed in SHR did
-
-, not appear to be secondary to an increase in neurally mediated
vasoconstrictor tone [78]. The apparent discrepancies among
- — studies have been attributed to methodologic differences such
—
as mode of anesthesia, methods of processing nerve signals, or
—
- / / different sources of animals, but the differences have not been
- fully explained [77].
Evidence exists that alterations in the numbers and/or bind-
p<.001 p<.001 p-<005 ns ing characteristics of adrenergic receptors in the SHR kidney
8 12 might play a role in the pathogenesis of hypertension, presum-
ably by giving rise to exaggerated or inappropriate renal reten-
tion of sodium. Increased density of and J31-adrenergic
receptors has been demonstrated in renal membrane prepara-
tions from SHR compared with age-matched WKY controls
[79, 801. When the SHR was challenged with salt-loading, both
the o and /3 receptors were signifiantly upregulated [81]. The
SHR fed a high-salt diet also showed a substantial rise in blood// pressure. To obtain an index of a2-adrenergic receptor density
and affinity, [H] para-aminoclonidine was bound to crude
membrane preprations from kidney. Our preliminary evidence
revealed two binding sites in SHR kidney [82]. The high-affinity
site had a Kd of 0.54 nM and a V,, of 47 fmol/mg protein; the
low-affinity site had a Kd of 4.4 nM and a Ymax of 132 fmol/mg
protein. Age-matched WKY kidneys did not contain the high-
affinity site. These data do not permit us to determine whether
there are two distinct binding sites for PHI para-aminoclonidine
_______________________________________
in rat kidney or a single receptor with different affinity states.
7 8 10 11 12 The higher affinity site does appear to be altered in SHR,
however. Previous studies have shown that isolated perfusedWeeks of age
kidneys from SHR reabsorbed more sodium than did kidneys
from normotensive rats when aradrenergic receptors were
stimulated by the addition of norepinephrine to the perfusate
1831. This finding supports the conclusion that the increased
number of s2-adrenergic receptors in the kidney of SHR was
associated with increased sodium retention. Thus, a probable
locus of the genetically linked renal-neural abnormality that
predisposcs to the development of hypertension in SI1R is the
cs2-adrenergic receptor site on the proximal tubule. Further
study is needed to assess renal a2-adrencrgic receptor function
in other experimental models of hypertension and in hyperten-
sive patients to determine whether this abnormality is shared by
other forms of hypertension.
The Dahi S rat. Increased density of a2-adrenergie receptors
in renal membrane preparations in Dahi salt-sensitive (S) rats
compared with membranes from DahI salt-resistant (R) rats has
been demonstrated when both groups were ingesting a low-
sodium diet [841. Further, when challenged with salt loading,
the DahI R rats showed little change in renal 2-receptor
density, whereas the Dahi S rats developed significant increases
in renal a2-receptor concentration [841. Binding affinity (KD) of
the s, receptors did not differ between S and R groups and
decreased only marginally in S rats on a high-salt diet. The
density of x receptors did not differ between strains or between
dietary regimens. Because renal 2 receptors are located pri-
marily on proximal tubules at sites where norepinephrine
release induces sodium reabsorption, this genetically deter-
Fig. 8. Top panel: Systolic blood pressures of renal denervated and
sham-operated spontaneously hypertensive rats (SHR). The arrow
indicates time of operation. Bottom panel: Corresponding values for
mean weekly fraction of ingested sodium excreted in the urine (FENO) in
the two groups. P values refer to comparisons between groups using
Student's t-test for unpaired data. Note that the reduction in blood
pressure in the denervated rats is mirrored by an increase in sodium
excretion in the same animals, thus suggesting that the renal nerves are
responsible for excessive sodium retention in the young STIR. Re-
printed with permission from [85].
nerves do not appear to contribute to the maintenance of
established hypertension.
The observation that the renal nerves play a role in the
development of hypertension in the SHR is consistent with
earlier demonstrations of increased sympathetic nervous sys-
tem activity in this model [68—76]. Concentrations of catechol-
amines and catecholamine synthesizing enzymes in individual
brain stem and hypothalamic nuclei of SHR have been shown to
differ from those of control Wistar-Kyoto (WKY) rats [72—74,
761. Further, treatment with central as well as peripheral
sympatholytic agents has been shown to delay and attenuate the
development of hypertension in the SHR 168, 71]. In addition,
direct measurements of pre- and postganglionic sympathetic
nerve activity have shown that nerve traffic in SHR is increased
in comparison with age-matched WKY controls [69, 701.
Thoren and Ricksten found efferent renal sympathetic nerve
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mined abnormality in receptor regulation could contribute to
the pathogenesis of hypertension by predisposing to exagger-
ated sodium retention.
The DOCA-NaC1 hypertensive rat. As in the SHR, increased
renal efferent nerve activity contributes to the development of
hypertension in DOCA-NaC1—treated rats by causing increased
renal sodium retention [85, 86]. Renal denervation carried out
prior to initiation of DOCA-NaC1 treatment delays the devel-
opment and blunts the severity of hypertension [86]. The delay
in the development of hypertension is associated with increased
urinary sodium excretion, suggesting a renal efferent mecha-
nism. As in the young SHR, the subsequent development of
hypertension in denervated animals correlates with increased
urinary sodium retention and increasing renal norepinephrine
stores, suggesting reinnervation.
To assess the role of the renal nerves in the maintenance of
DOCA-NaCl hypertension, we subjected DOCA-NaCI hyper-
tensive animals to renal denervation after 3 and 10 weeks of
treatment [87]. In animals treated with DOAC and NaCl for 3
weeks (the 3-week DOCA-NaC1—treated animals), renal dener-
vation was followed by an attenuation in the severity of the
hypertension associated with a natriuresis. In contrast, neither
blood pressure nor sodium excretion was altered following
renal denervation in hypertensive animals treated with DOCA
and NaCI for 10 weeks. These data support a significant role for
the renal nerves in the initiation and early maintenance phases
but not in the established phase of hypertension.
In 3-week DOCA-NaC1 hypertensive animals, renal precapil-
lary arteriolar wall-to-lumen ratios were significantly increased
as compared with vessels of similar size in hindlimb and
cremaster muscle [87]. In contrast, renal precapillary arteriolar
wall-to-lumen ratios of renal-denervated DOCA-NaC1—treated
animals were no different from those of vessels of similar size in
hindlimb and cremaster muscle. The natriuresis and lowering of
arterial pressure seen in the 3-week DOCA-NaC1 treated ani-
mals following denervation were associated with a reduction in
the precapillary arteriolar wall-to-lumen ratio in the kidney.
These observations suggest that (I) there was a disproportion-
ate increase in efferent renal sympathetic nerve activity in rats
at this stage of DOCA-NaCl hypertension and (2) the blood
pressure-lowering effect of renal denervation was due to a
leftward shift in the arterial pressure-sodium excretion curve
for the kidney. Further, renal denervation in the 3-week DOCA-
NaC1—treated animals decreased the renal precapillarly arterio-
lar wall-to-lumen ratio without altering the wall-to-lumen ratio
of larger intrarenal vessels, suggesting that the efferent renal
nerves selectively influence the renal precapillary arteriole and
not the larger intrarenal vessels at this stage in DOCA-NaCI
hypertension. The selective effect of renal nerves on the renal
precapillary arteriole might be due to increased sensitivity to
locally (neurally) released vasoactive substances or to tropic
influences.
In contrast, the 10-week DOCA-NaCI--treated animals had
renal precapillary arteriolar wall/lumen ratios that were no
different from those in similar-sized vessels in hindlimb and
cremaster muscle [87]. Further, the renal precapillary arteriolar
wall/lumen ratio was not altered by renal denervation, and the
creatinine clearance was significantly lower than that of the
3-week animals. Thus, although the renal nerves appear to play
a diminishing role in the maintenance of established DOCA-
NaCI hypertension in the rat, other factors, including decreased
glomerular filtration rate, fixed renal vascular changes, in-
creased vasopressin release, increased peripheral vascular re-
activity, and increased sympathoadrenal activity, play increas-
ingly important roles [87, 88].
Essential hypertension in humans
Increased sympathetic nervous system activity has been
implicated in the initiation and maintenance of primary, or
essential, hypertension in humans. Patients with early or labile
hypertension commonly manifest hemodynamic characteris-
tics, including tachycardia, increased cardiac output, increased
dp/dt, and venoconstriction with a normal total peripheral
resistance, which suggest hyperactivity of the sympathetic
nervous system [61, 89]. A positive correlation between plasma
norepinephrine levels and diastolic blood pressure has been
found in patients with labile hypertension, further supporting a
role for increased sympathetic activity in the pressure elevation
[901. Further, elevated cerebrospinal fluid norephrine concen-
trations, suggesting increased activity of central noradrenergic
neurons, have been found in patients with essential hyperten-
sion but not in healthy normal volunteers [91].
Patients with primary hypertension have been identified who
have elevated circulating norepinephrine levels [92—94] as well
as exaggerated depressor responses to the a-adrenergic recep-
tor agonist clonidine [95]. The latter observations suggest that
increased central sympathetic outflow might play a pathophys-
iologic role in some patients with essential hypertension. The
association of increased plasma catecholamine and renin levels
in hypertensive patients [961 further suggests that increased
neural activity might effect elevations in blood pressure via
activation of the renin-angiotensin system or other humoral
mechanisms.
An increase in renal vascular resistance has been one of the
most consistent abnormalities documented in essential hyper-
tension [61, 97—1021. Resting renal blood flow is reduced in the
majority of patients with benign essential hypertension. Evi-
dence indicates that in many patients with essential hyperten-
sion of recent onset, the increased renal vascular resistance
represents a functional abnormality. The functional, dynamic
nature of the renal vasoconstriction is illustrated by the marked
variability in sequential renal blood flow determinations ob-
served in these patients [97]. Further, selective renal angi-
ograms in patients with essential hypertension have shown
narrowing and tortuosity of the distal interlobar and arcuate
arteries; these findings disappear after infusion of vasodilators
[99].
The renal vasoconstriction in patients with essential hyper-
tension of recent onset is sympathetically mediated [61, 100,
103]. Alpha-adrenergic blockade with phentolamine has no
effect on renal blood flow in sodium-replete normotensive
subjects, but it increases renal blood flow and reverses renal
angiographic abnormalities in patients with essential hyperten-
sion [104, 105]. Additional evidence of increased renal norad-
renergic activity in patients with essential hypertension is
provided by the observation that renal blood flow is decreased
by intrarenal administration of low-dose propranolol, presum-
ably because of the unmasking by propranolol of high underly-
ing a-adrenergic tone [106]. Further, splanchnic blockade in-
creases renal blood flow in patients with essential hypertension,
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but not in normotensive control subjects [107, 108]. This
finding, coupled with the observation that renal vascular re-
sponsiveness to intravenous norepinephrine and epinephrine
infusions is normal in patients with essential hypertension [109],
suggests that the increased renal sympathetic activity is medi-
ated by the renal nerves. Finally, renal norepinephrine secre-
tion is increased in many patients with essential hypertension
compared with normotensive subjects, further supporting the
concept that the activity of efferent sympathetic nerves supply-
ing the renal vascular bed is stimulated in essential hyperten-
sion [1101.
Evidence also has demonstrated that the sympathetic activa-
tion in some patients with essential hypertension, particularly in
the early or labile phases of the disease, involves the renal
vascular beds to a greater degree than other vascular beds [105].
In a subset of patients with mild essential hypertension, periph-
eral venous levels of norepinephrine are normal, whereas renal
norepinephrine secretion is elevated [105, 1101. When norepi-
nephrine secretion by several organs was compared, renal
secretion was significantly greater than cardiac or hepatic
secretion in patients with essential hypertension [1051. Selec-
tive activation of sympathetic tone in the renal vascular bed
would stimulate the development of hypertension by shifting
the sodium excretion curve to the right [ill].
In contrast to patients with hypertension of recent onset or
labile essential hypertension, those with longstanding severe
hypertension have arteriolonephrosclerosis and an attenuated
renal vascular response to vasodilators [981. Renal blood flow
does not increase, and angiographic abnormalities are not
altered by, administration of acetylcholine into the renal artery,
suggesting a fixed vascular lesion. Thus the increased renal
vascular resistance in patients with essential hypertension
might be predominantly functional or structural, depending on
the stage of the hypertension [611. As hypertension becomes
chronic and severe, the role of fixed renal vascular lesions in its
maintenance is amplified, and that of the renal nerves is
diminished. Similar findings have been reported in the SHR and
DOCA-NaCI rat models of hypertension. Finally, the impor-
tance of the kidney in essential hypertension recently has been
emphasized by the observation that in some patients blood
pressure became normal after removal of end-stage native
kidneys and transplantation of a kidney from a normotensive
donor [112].
Summary
In summary, many lines of evidence indicate that the sym-
pathetic nervous system, via the renal nerves, plays an impor-
taut role in the pathogenesis of renovascular hypertension in
humans and laboratory animals. Patients with established reno-
vascular hypertension have increased sympathetic nervous
system activity, as evidenced by increased plasma and urinary
norepinephrine levels, elevated excretion of catecholamine
metabolites, and an exaggerated depressor response to cen-
trally acting sympatholytic agents. The observation that con-
verting enzyme inhibitors can cause both blood pressure and
urinary norepinephrine excretion to return to normal in patients
with rcnovascular hypertension is consistent with the interpre-
tation that activation of the sympathetic nervous system in
these subjects is, at least in part, angiotensin-induced.
The sympathetic nervous system, via the efferent renal
nerves, plays a role in the pathogenesis of hypertension in a
number of experimental models. In the spontaneously hyper-
tensive rat of the Okamoto strain (SHR) and in the DOCA/NaCl
hypertensive model, increased renal efferent nerve activity
contributes to the development of hypertension by causing
increased renal sodium retention. In both of these experimental
models, renal denervation delays the development and blunts
the severity of hypertension. This delay is associated with
increased urinary sodium excretion, suggesting a renal efferent
mechanism. In contrast to the predominantly efferent renal
nerve mechanisms observed in the DOCA-NaC1 and SHR
models, studies of the effects of renal denervation in one-
kidney, one-clip and two-kidney, one-clip Goldblatt hyperten-
sive rats suggest that renal afferent nerves are important in
these models of hypertension. Total renal denervation in rats
with established 1K,IC and 2K,1C hypertension attenuates the
severity of the hypertension without altering sodium intake or
excretion, renin activity, water intake, or renal function. Thus,
efferent renal nerve activity does not appear to be involved in
the development of maintenance of IK,IC or 2K,IC hyperten-
sion. In contrast with the findings in SHR and I)OCA-NaC1
rats, these studies provide indirect evidence that the renal
afferent nerves play a role in the pathogenesis of this form of
experimental hypertension. The major effect of renal denerva-
tion in these models appears to be an interruption of renal
afferent nerve activity, which by a direct feedback mechanism
attenuates systemic sympathetic tone, thereby lowering blood
pressure. indirect support for this hypothesis comes from
anatomic and physiologic studies in which renal afferent fibers
were shown to project centrally to the intermediolateral cell
column in the spinal cord and to the medulla, a region involved
in cardiovascular regulation. Direct support for this hypothesis
comes from recent studies in which the effect of rhizotomy of
the appropriate (T8-L2) dorsal spinal nerves on the subsequent
course of blood pressure in the 1K,1C rat was assessed.
Rhizotomy produced an attenuation in the severity of IK,IC
hypertension similar in magnitude to that observed with total
peripheral renal denervation. Failure of blood pressure to
return to normal following either intervention suggests that
factors other than the renal nerves contribute to the develop-
ment and maintenance of hypertension in this model.
Questions and answers
DR. PATRICIA MCELROY (Cardiology Division, Michael
Reese Hospital, Chicago, Illinois): My understanding is that
norepinephrine is, for the most part, released locally rather than
into the circulation, If this is true, can one safely rely on blood
norepinephrine levels as an accurate indicator of sympathetic
activity? Why would arterial values be more useful than venous
values?
DR. OPARIL: Norepinephrine release is local in the sense that
norepinephrine goes from the neuron to the synaptic cleft and
then must diffuse through a number of barriers to enter the
blood. Accordingly, plasma norepinephrine concentration is
not the most sensitive index of neuronal activity. Spillover into
the circulation from the site of production depends on many
factors, as 1 mentioned earlier. To obtain a truly accurate index
of sympathetic activity, it would be necessary to insert a
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detecting device into the synaptic cleft and measure levels of
norepinephrine there. No one has ever done that successfully.
Attempts have been made to quantify neurotransmitter re-
lease in brain in vivo, however, using the push-pull perfusion
technique and in-vivo voltammetry. Push-pull perfusion is
accomplished by implanting a double-barreled cannula near a
neuronal group of interest, then bathing the neurons through the
inner cannula with artificial spinal fluid or with a solution
containing appropriate pharmacologically active agents. Perfus-
ate is then withdrawn from the outer cannula and subjected to
analysis for neurotransmitters and their metabolites. in-vivo
voltammetry involves insertion of a cannula, which is coated
with a film of biochemically selective material, into the region of
a targeted neuronal group, then measuring the potential created
by catecholamines released from the neurons. Detection and
quantification of monoamines are accomplished as in high-
performance liquid chromotography with electrochemical de-
tection [113].
The most accurate index of total sympathetic outflow from
the brain is nerve traffic in a major sympathetic nerve, such as
the greater splanchnic, lumbar, or renal nerve. One problem
with nerve traffic recording techniques is that they are techni-
cally difficult, particularly in conscious, freely moving small
animals, such as the rat. Another difficulty relates to the
inhomogeneity of activity in sympathetic nerves supplying
various vascular beds, for example, mesenteric versus renal
versus skeletal muscle, Because of the difficulty inherent in all
these techniques, plasma norepinephrine is still the most widely
accepted and widely applied method of assessing sympathetic
activity. Arterial levels of norepinephrine tend to be more
reliable than are venous levels because there is denser innerva-
tion of resistance vessels—so the circulating blood is closer to
the source of norepinephrine.
DR. JORDAN J. COHEN (Chairman, Department of Medicine,
Michael Reese Hospital): Renovascular hypertension is en-
countered with some frequency in renal transplant patients. Yet
in this circumstance the kidney is completely denervated, or at
least the normal afferent connections with the central nervous
system are permanently disrupted. How do you view the
pathogenesis of hypertension under these circumstances?
DR. OPARIL: Hypertension occurring de novo in renal trans-
plant recipients is thought to be related to either pressor
substance, presumably renin and angiotensin II, produced by
the native kidneys, or to stenosis in the transplant's renal artery
at the site of anastomosis. Depending on the time of onset of the
hypertension, it is conceivable that nerves supplying the tralis-
planted kidney could participate in at least the maintenance, if
not the initiation, of renovascular hypertension. Gazdar and
Dammin demonstrated regenerating axons distal to the arterial
anastomosis as early as 28 days following human renal trans-
plantation [114]. Regenerating axons could be traced to the
nerves accompanying the interlobular arteries, and, in long-
surviving renal allografts, to renal arterioles.
Increased renal nerve activity is probably unnecessary in the
acute phase of renovascular hypertension. This mechanism
comes into play later—during the maintenance phase of the
hypertension. In general, the renin-angiotensin system is acti-
vated acutely as the renal artery is occluded, and angiotensin II
mediates the acute rise in blood pressure. Later, the activity of
the renin-angiotensin system decreases and sympathetic activ-
ity increases. Two of my colleagues at Alabama. Richard
Katholi and Patrick Whitlow, have studied this phenomenon in
dogs [102, 115]. They made a coarctation model of hypertension
by placing a balloon catheter on the thoracic aorta that could be
inflated in the conscious animal, thus creating an acute coarcta-
tion. They showed that plasma renin is elevated and plasma
norepinephrine depressed immediately following inflation of the
balloon. At that time, the depressor response to alpha-adren-
ergic blocking drugs is attenuated. In contrast, during the
chronic phase of coarctation hypertension, plasma norepineph-
rine is increased, whereas plasma renin activity falls and the
depressor response to alpha-adrenergic blockers is increased,
reflecting an increase in the relative importance of sympathetic
neural mechanisms in the maintenance phase of the hyperten-
sion. Because of this chronology, it is conceivable that regen-
erated renal nerves are involved in the maintenance phase of
hypertension secondary to renal artery stenosis associated with
transplantation.
DR. DAVID BUSHINSKY (Renal Section, Mitchell Hospital,
Chicago): Do you advocate measuring norepinephrine levels in
patients with renovascular hypertension, or perhaps even in
those with essential hypertension? If so, would you use a
sympatholytic agent such as clonidine in the treatment of those
with elevated values?
DR. OPARIL: No. Measurements of plasma norepinephrine in
this situation are useless except in dedicated laboratories that
are experienced in both assay methods and sampling tech-
niques. The slightly elevated norepinephrine levels in patients
with renovascular hypertension are not clearly separable from
the normal range. Further, even in normal individuals, circu-
lating norepinephrine levels are labile, depending on the
patient's state of arousal. To obtain a blood sample for valid
plasma norepinephrine measurement, the patient must be at
rest, and the pain of venipuncture must be avoided, because it
is associated with a tremendous increase in norepinephrine
levels. Therefore a needle must be kept in the vein for one-half
hour or more prior to drawing blood. Further, if the patient is
anxious, you are likely to find perturbations of norepinephrine
levels, So I don't think that sampling of plasma norepinephrine
levels is worthwhile in the evaluation of patients with renovas-
cular hypertension. Instead, I would suggest an empiric trial of
clonidine or alpha methyldopa for patients with renovascular
hypertension whose blood pressure is poorly controlled with
other agents.
DR. BUSHINSKY: In the one clip, one- or two- kidney
Goldblatt models, unclipping the renal artery returns blood
pressure to normal, yet denervation never quite achieves the
same result. To what do you attribute the residual hyperten-
sion? Have you tried to ameliorate the residual hypertension
with clonidine?
DR. OPARIL: No. We haven't administered clonidine to
denervated animals. We are not sure why the blood pressure in
animals with unclipped kidneys completely returns to normal,
whereas that in animals with denervated kidneys is attenuated
but never returns to normal. Eric Muirhead has produced data
suggesting that the restoration of normal blood pressure after
tinclipping is due to release of a vasodilator, a renal medullary
neutral lipid [116, 117]. Muirhead has evidence that circulating
levels of this compound are increased after unclipping in both I-
and 2-kidney Goldblatt models. Another possible explanation
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for the residual hypertension after renal denervation is that the
mechanisms underlying the maintenance of the hypertension
are multiple, with increased neural activity being only one of
these. Following denervation, the stenotic kidney continues to
produce large amounts of refill and angiotensin, renal blood
flow remains suppressed, and some level of secondary renal
dysfunction, with attendant inability to handle a volume load
appropriately, persists. All these factors can contribute to the
maintenance of hypertension. Further, animals with chronic
renovascular hypertension may have increased fixed peripheral
vascular resistance due to hypertension-induced structural al-
terations in the resistance vessels.
DR. MARSHALL LINDHE!MER (Renal Section, Mitchell Has-
pita!): In some of your examples, hypertension was associated
with catecholamine levels that are not usually associated with
high blood pressure. Yet mean arterial pressure was reduced
when norepinephrine levels were lowered. Some of the drugs
that lower norepinephrine also can lower circulating vasopres-
sin (AVP), a substance that some authors believe has a "facil-
itating effect" on the pressor action of norepinephrine. Would
you care to comment on these points?
DR. OPARIL: I don't really want to comment on the AVP
issue because I don't have enough relevant data. We have never
studied the role of AVP in the maintenance of renovascular
hypertension. Your comment that the levels of circulating
norepincphrine that we saw in renovascular hypertension,
which were about twice normal, are not sufficiently elevated to
produce an increase in blood pressure by themselves is correct
and ties in very well with Pat McElroy's question. That is, as
has been nicely shown by Phil Cryer at Washington University,
St. Louis, circulating levels of exogenous norepinephrine of this
magnitude would not elevate blood pressure 11181. However,
the endogenous plasma norepinephrine in our rats with reno-
vascular hypertension comes mainly from the sympathetic
nerves and must diffuse or be transported great distances in
order to enter the blood. Therefore it is probable that concen-
trations of norepinephrine are very high in the synaptic clefts of
these animals, accounting for high levels of vascular tone by
activating noradrenergic receptors on vascular smooth muscle.
DR. CoHEN: You indicated that denervating a normal kidney
that does not have a renal artery clip in place has no demon-
strable effect on blood pressure. Would that imply that the
mechanism you are invoking as a partial explanation for hyper-
tension in renovascular disease does not have a physiologic role
in the normal control of blood pressure?
DR. OPARIL: Our observation was that denervation of the
contralateral, nonclipped kidney in the 2K,lC model of hyper-
tension did not alter blood pressure 1551. This is different from
denervating one or both renal arteries in a normal subject. I
would not interpret our data as suggesting that the renal nerves
play no physiologic role in the control of normal blood pressure,
as we were not dealing with a normotensive animal. Tradition-
ally, the role of the renal nerves in the control of blood pressure
and water and electrolyte balance has been thought to be
minimal [108]. In conscious animals studied under basal condi-
tions, levels of efferent renal sympathetic nerve activity are
low, and pharmacologic or surgical interruption of the renal
nerves results in no change in renal blood flow and little effect
on sodium excretion 1108, 119]. Yet even the low levels of
efferent renal nerve activity that are recorded in conscious
animals under basal conditions can influence circulatory homeo-
stasis by regulating the activity of the renin-angiotensin system
and renal tubular water and electrolyte excretion. It has been
shown that low levels of efferent renal nerve activity increase
renin secretion rates at normal renal perfusion pressures in the
absence of changes in glomerular filtration rate, renal blood
flow, or urinary sodium excretion [120, 121]. In addition, low
levels of efferent renal nerve activity increase proximal tubular
sodium and water reabsorption and loop of Henle sodium and
chloride reabsorption without changing renal blood flow, sug-
gesting that the renal nerves contribute to cardiovascular regu-
lation in the conscious normotensive animal [122, 123]. Several
studies in conscious animals and humans indicate that intact
renal innervation is important for the maintenance of sodium
balance. Chronic renal denervation induces a diuresis and
natriuresis in conscious rats on normal dietary sodium intake
[124]. Further, renal denervation has been found to impair the
ability of the kidney to conserve sodium when animals are
placed on a low-sodium diet [125—127]. In patients with idio-
pathic autonomic insufficiency (Shy-Drager syndrome) or nor-
mal subjects with guanethidine-induced autonomic insufficiency
who are maintained on a sodium-restricted diet, the kidneys are
unable to conserve sodium, resulting in a negative sodium
balance and weight loss [128, 1291. Several lines of evidence
thus support a role for the renal nerves in the maintenance of
cardiovascular homeostasis in normotensive subjects, particu-
larly under conditions of environmental stress.
DR. KARL WEBER (Cardiology Division, Michael Reese Hos-
pital): It seems to me that if you used larger animals, such as
dogs, you could implant catheters in both renal veins and place
an inflatable cuff on one renal artery; with this model, one could
create reversible stenosis. By releasing the stenosis, one could
measure the time course over which plasma norepinephrine is
released from the affected kidney and from the contralateral
control kidney. This option is not possible in the rat because of
its size. Why hasn't someone used the dog model to demon-
strate the role of the sympathetic nervous system?
DR. OPARIL: That is an excellent suggestion and would be a
good experiment. Katholi and Whitlow have done similar
experiments in the canine coarctation model [115j. We haven't
done these studies because they are technically difficult and
expensive. Barger carried out similar experiments to elucidate
the role of the renin-angiotensin system in the pathogenesis of
renovascular hypertension, but he did not use the model to
study neural mechanisms.
i)R. ANTONIO QUINTANILLA (Renal Section, Veterans Ad-
ministration Lakeside Hospital, Chicago): I believe that some
nerve fibers are actually imbedded in the arterial wall. if that is
the case, then the completeness of the denervation in your
experiments comes into question.
DR. OPARIL: Correct. You do not get complete renal denerva-
tion, as signified by complete disappearance of norepinephrine
stores in the kidney, using the phenol denervation technique.
The denervation procedure is fairly rigorous and traumatic to
the renal artery, however, You paint 20% phenol on the renal
artery, and everything turns gray. You probably kill the first
few layers of cells on the outside of the renal artery, and if you
are not careful, you can traumatize the renal artery through and
through, with resultant problems with intravascular clotting.
The only practical way to produce complete denervation would
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be to autotranspiant the kidney to another region of the body, a
technically difficult feat. Renal autotransplantation could be
carried out more easily in the dog than in the rat, but dogs don't
develop renovascular hypertension as easily as rats do, presum-
ably because the dog kidney retains sodium less avidly.
DR. JOHN WYNN (Medical Resident, Michael Reese Hospi-
tal): Could you comment on the possible effects of damage,
destruction, or removal of the adrenal glands during the various
operative procedures used in creating your experimental mod-
els? How do you control for these effects?
DR. OPARIL: We try to be careful to leave the adrenal glands
in, in general, you can tell how the adrenal medulla is doing by
measuring circulating epinephrine levels. In our rats with
renovascular hypertension, plasma epinephrine levels have
always been in the normal range, indicating that the adrenal
medullas are intact and functioning.
Da. KAT LAU (Renal Division, Michael Reese Hospital):
What is the mechanism by which the afferent nerves contribute
to the hypertension? It would appear that the increased renal
excretion of sodium following denervation is not great enough
to play much of a role. Is there any evidence that neutral lipids
are involved?
DR. OPARIL: We think that a conversation between the
kidney and the brain is mediated by the afferent renal nerves
and that the afferent nerves increase central sympathetic dis-
charge by modulating the functions of certain important hypo-
thalamic neuronal groups. The stimulus for activation of the
afferent renal nerves is not known. As I mentioned earlier,
Katholi has developed the hypothesis that adenosine activates
the renal afferent nerves via chemoreceptors in the renal pelvis
or renal vasculature. Further, elegant electrophysiologic data
from Calaresu in London, Ontario [130], and also from Simon
and Schramm at Johns Hopkins [131] indicate that if you divide
the renal nerve and then stimulate the proximal cut end, the
activity in many populations of hypothalamic neurons is al-
tered. Some neurons show increased activity, others, inhibited
activity. Thus, the electrical connections between kidney and
brain are complex—afferent renal nerve to hypothalamus to
brain stem—and these connections appear to influence sympa-
thetic outflow. Teleogically, it is not clear why the body would
want to have such a modulatory mechanism, unless by raising
blood pressure in an individual with impaired renal blood flow
secondary to a stenosed renal artery, the body is attempting to
restore renal blood flow to normal levels. It is probable that
intrarenal chemoreceptors rather than baroreceptors are in-
volved in this pathway, because baroreceptor sensitivity tends
to extinguish over time, and the renal nerve influence seems, if
anything, to increase over time. We think that afferent renal
nerve function is important in both the coarctation model and
the renovascular hypertension models. In the DOCA-salt rat
and the SHR, changes in sodium excretion occur following
renal denervation, so efferent renal nerve function seems to be
important. Whether the afferents play an important role in the
SHR as well, I don't know.
DR. WEBER: The heart also has its circulation frequently
stenosed. When the coronary arteries are obstructed, adenosine
levels in the myocardium increase, but I am not aware that the
myocardium releases catecholamines in response to all that
adenosine, I certainly don't think that coronary artery disease
leads to systemic hypertension. What is it about the kidney and
its few picograms of norepinephrine that leads to hypertension?
DR. OPARIL: Our hypothesis is not that the adenosine re-
leases norepinephrine locally, but rather that adenosine acti-
vates chemoreceptors in the kidney that cause increased af-
ferent renal nerve traffic, activation of critical hypothalamic
centers, and increased sympathetic outflow. Whether the aden-
osine receptors are in the renal arteries, in the renal pelvis, or
elsewhere is not clear. Afferent neurons probably do not use
norepinephrine as their transmitter; substance P, glycinc, and
some other amino acids and polypeptides are more likely
candidates. There is, in fact, evidence that myocardial ischemia
is associated with depletions in myocardial norepinephrine
stores, The mechanism of these depletions is unclear: specifi-
cally, it is not known whether hypoxia per se causes neurons to
release transmitter. It is known, however, that myocardial
ischemia can trigger cardiac reflexes. For example, Dr. Thomas
James has described a pressor reflex that is triggered by
myocardial ischemia [1321. James and his colleagues have
learned that injection of serotonin into the left atrium or
selected regions of the coronary bed in dogs produces a
transient acute pressure response that resembles in every way
the reflex triggered by myocardial ischemia [133]. They rea-
soned that the ischemia-triggered response might be dependent
on serotonin released from aggregated platelets in the coronary
circulation during periods of ischemia.
DR. LINDHEIMER: Perhaps I misinterpreted your remarks,
but did you say that "all" hypertensive models require a period
of sodium retention if hypertension is to develop? I thought that
there were models of renal artery stenosis in which blood
pressure rises in response to sodium depletion and falls with
saline infusion.
DR. OpARIL: I didn't mean to make that statement. Sodium
retention is certainly much more important in the pathogenesis
of IK,IC Goldblatt hypertension than in 2K,lC hypertension,
and a period of sodium retention may not be required for the
development of hypertension in the latter model. Tobian and
associates have demonstrated that exchangeable sodium is
approximately 10% higher in the IK,IC Goldblatt hypertensive
rat than in the 2K,1C model. Further, Swales and colleagues
have shown that cumulative sodium balance is generally nega-
tive or normal following renal artery constriction in the 2K,IC
rat, and generally positive after renal artery constriction in the
1K,lC model [134]. In the 2K,lC model, sodium balance
depends on the severity of hypertension: rats with more severe
hypertension have more negative sodium balance, presumably
secondary to pressure diuresis in the nonclipped kidney. You
are correct that blood pressure rises in response to sodium
depletion in some models of renovascular hypertension. Swales
demonstrated that removal of sodium by peritoneal dialysis can
cause blood pressure to increase in 2K,lC Goldblatt hyperten-
sive rats, whereas similar volume depletion carried out in the
IK,IC model results in a fall in blood pressure. Presumably this
reflects the greater angiotensin dependence of blood pressure in
the 2K,1C model.
Reprint requests to Dr. S. Oparil, Hypertension Research Program,
Room 1012, Zeigler Research Building, University (f Alabama at
Birmingham, University Station, Birmingham, Alabama 35294, (ISA
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